CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.

@article{Gillmore2021CRISPRCas9IV,
  title={CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.},
  author={Julian D. Gillmore and E. H. Gane and Jorg Taubel and Justin C. Kao and Marianna Fontana and Michael L. Maitland and Jessica Seitzer and Daniel O’Connell and Kathryn R Walsh and Kristy Wood and Jonathan Phillips and Yuanxin Xu and Adam Amaral and Adam P. Boyd and Jeffrey E Cehelsky and Mark McKee and Andrew Schiermeier and Olivier A. Harari and Andrew Murphy and Christos A. Kyratsous and Brian Zambrowicz and Randy Soltys and David E. Gutstein and John Leonard and Laura Sepp-Lorenzino and David Lebwohl},
  journal={The New England journal of medicine},
  year={2021}
}
BACKGROUND Transthyretin amyloidosis, also called ATTR amyloidosis, is a life-threatening disease characterized by progressive accumulation of misfolded transthyretin (TTR) protein in tissues, predominantly the nerves and heart. NTLA-2001 is an in vivo gene-editing therapeutic agent that is designed to treat ATTR amyloidosis by reducing the concentration of TTR in serum. It is based on the clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease (CRISPR-Cas9… 

Figures from this paper

Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies
  • A. Warner
  • Biology, Medicine
    Pharmacotherapy
  • 2021
Transthyretin cardiac amyloidosis (ATTR‐CA) has been recognized as an underdiagnosed and undertreated cause of heart failure with often unrecognized multiorgan involvement. Guideline development and
Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis
TLDR
The current advances in treating ATTRv amyloidosis have become a meaningful example for mechanism-based treatment and will still have to face new challenges including shifts in the phenotype spectrum and the ongoing need for improved treatment precision.
CRISPR/Cas-Based Gene Editing Strategies for DOCK8 Immunodeficiency Syndrome
TLDR
The findings encourage the pursuit of CRISPR/Cas-based gene editing approaches, which may constitute more precise, affordable, and low-risk definitive treatment options for DOCK8 deficiency.
CRISPR/Cas9-Mediated Excision of ALS/FTD-Causing Hexanucleotide Repeat Expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro
A hexanucleotide repeat expansion (HRE) consisting of GGGGCC24+ in the C9ORF72 gene is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Both are
Transthyretin: Its function and amyloid formation
  • M. Ueda
  • Biology
    Neurochemistry International
  • 2022
In vivo targeting of a variant causing vanishing white matter using CRISPR/Cas9
Rationally designed nanoparticle delivery of Cas9 ribonucleoprotein for effective gene editing.
Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis
TLDR
The considerable therapeutic advances have raised additional challenges, including optimisation of diagnostic techniques and management approaches in ATTRv neuropathy, as well as improvement in quality of life and functional outcomes.
Gene editing in patients with amyloidosis
TLDR
The gene therapy was well tolerated, with no increase in mortality compared with controls and without signs of arrhythmia or tumour formation in the liver or lungs, and seemed to be cardiomyocyte-specific.
Exploiting HIV‐1 tropism to target CD4+ T cells for CRISPR
TLDR
The use of VLPs as a vector to introduce Cas9 proteins into cells is not novel, but a system that shuttles Streptococcus pyogenes Cas9 RNPs into cells utilizing retrovirus-like particles (VLPs) is reported, allowing for the ability to target specific cell subsets in a mixed population, at least in vitro.
...
...

References

SHOWING 1-10 OF 39 REFERENCES
Targeting transthyretin ‐ Mechanism‐based treatment approaches and future perspectives in hereditary amyloidosis
TLDR
This systematic review summarizes the current literature on TTR pathophysiology with its therapeutic implications and indicates that further understanding of disease mechanisms will help to overcome the remaining limitations, including application burden, side effects, and blood–brain barrier permeability.
Evolving landscape in the management of transthyretin amyloidosis
TLDR
The TTR stabilizers tafamidis and diflunisal slow disease progression in some patients with ATTR amyloidosis with polyneuropathy, and the postulated synergistic effect of doxycycline and tauroursodeoxycholic acid on dissolution of amyloids is under investigation.
Emerging therapies in transthyretin amyloidosis – a new wave of hope after years of stagnancy?
TLDR
targeted therapies, which aim to interfere with the deposition of misfolded transthyretin (TTR) at various stages of the cascade underlying ATTR progression, are explained and suggestions for future clinical research into the field are provided.
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
TLDR
Patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis with polyneuropathy and showed an effect on gait speed and modified BMI.
Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis
TLDR
Inotersen targets the disease-forming protein, TTR, and has been shown to improve quality of life and neuropathy progression in patients with stage 1 or 2 ATTRv with polyneuropathy, and is well tolerated, with a manageable safety profile through regular monitoring for the development of glomerulonephritis or thrombocytopenia.
A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
TLDR
Patisiran, a novel drug, is a liposomal siRNA against TTR that specifically targets this protein, reducing the accumulation of TTR in tissues, with subsequent improvement in both neuropathy and cardiac function.
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
TLDR
In patients with transthyretin amyloid cardiomyopathy, tafamidis was associated with reductions in all‐cause mortality and cardiovascular‐related hospitalizations and reduced the decline in functional capacity and quality of life as compared with placebo.
A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis
TLDR
The mechanism of cleavage and release of the 49–127 fragment from the prototypic S52P variant is investigated, and it is proposed that a mechano‐enzymatic mechanism mediates transthyretin amyloid fibrillogenesis in vivo.
...
...